‹ ›
MYP_013612
← PREVIOUS NEXT → BACK
Basic Information
LP-69
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
not Standard
21 amino acids
-
contains X representing unresolved or non-standard residue
Sequence
IEELLKKAEEQQKKNEEELKX
Physicochemical Analysis
0.00 Da
0.00
0.00
0.00
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0147073 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Acetylation
Amidation
The 'X' at position 21 is Lys-Chol(cholesterol)
Bio-Activity Profile
Antimicrobial Antiviral
6(R5X4):inhibition of virus replication in TZM-bl cells
0.004781±0.000699 μM
IC50
PaperPubMed PMID: 30867304 PMID30867304 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30867304/
RECORD: Rec_0152433 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
unspecified non-canonical residue at 21
Bio-Activity Profile
Antiviral
HIV-1 HxB2
PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0166323 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
Acetylation
Amidation
The 'X' at position 21 is Lys-Chol(cholesterol)
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 pseudovirus | TZM-bl cells
0.00014888 μM
IC50
Mammalian: 20 h; Yeast: 30 min; E. coli: >10 h
PaperDesign and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity. | Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y. | J Virol. 2019 May 15;93(11):e02312-18. | DOI:10.1128/JVI.02312-18 | PMID:30867304 PMID30867304 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30867304/
RECORD: Rec_0168758 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
unspecified non-canonical residue at 21
Bio-Activity Profile
Antiviral
HIV-1 NL4-3 D36G
PMID30089693 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30089693/
RECORD: Rec_0194295 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
noncanonical stereochemical modification [Modified]
Acetylation
Amidation
The 'X' at position 21 is Lys-Chol(cholesterol)
Bio-Activity Profile
Antiviral Anti-HIV Fusion inhibition
HIV-2 (ROD,ST) | TZM-bl cells
0.002857-0.013512 μM
IC50
Mammalian: 20 h; Yeast: 30 min; E. coli: >10 h
PaperDesign and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity. | Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y. | J Virol. 2019 May 15;93(11):e02312-18. | DOI:10.1128/JVI.02312-18 | PMID:30867304 PMID30867304 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30867304/
FIRST PREV 1 ... 3 4 5 6 7 ... 10 NEXT LAST
Showing 5 records on this page · Page 5 of 10